by dsaadmin | Announcement, Cosmetics
In the December 2015 update to the Cosmetic Ingredient Hotlist, a restriction was added to the Methylisothiazolinone/Methylchloroisothiazolinone (MI/MCI) entry. MI/MCI when used in combination is a prohibited substance in leave-on cosmetic products. An implementation...
by dsaadmin | Announcement, Medical Devices
Health Canada has announced that effective immediately evidence will be required to demonstrate that all hazards associated with thermal damage to the skin are eliminated or appropriately mitigated for light emitting medical devices. Affected devices include devices...
by dsaadmin | Announcement, Drugs
All non-prescription Category IV Monograph product (DINF) applications must include the new monograph attestation form. Due to unfavorable results of the monograph attestation pilot, Health Canada has put in place processes to ensure that all DINF applications comply...
by dsaadmin | Announcement, Uncategorized
As of June 1, 2016 Health Canada (HC) will no longer issue conditional registrations for pesticides. Currently conditional registrations may be granted to pesticide products when the scientific review determines that the risks of a pesticide are acceptable, but more...
by dsaadmin | Announcement, Drugs
The Active Pharmaceutical Ingredient (API) regulations came into force on November 8, 2013. After a three year transition, November 8, 2016 will mark the full implementation of the Regulations. Health Canada has posted several updates on changes that have been made to...
by dsaadmin | Announcement, GMP, Regulatory Submissions
Current Health Canada performance standards are at 250 days for approval of foreign sites. Foreign site approvals require submission of one of the following types of evidence. Regulatory Authority Inspection Report Certificate of GMP Compliance for MRA Countries...
